Synonyms
Status
Molecule Category Free-form
ATC J01DD01
UNII N2GI8B1GK7

Structure

InChI Key GPRBEKHLDVQUJE-QSWIMTSFSA-N
Smiles CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
InChI
InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H17N5O7S2
Molecular Weight 455.47
AlogP -0.62
Hydrogen Bond Acceptor 11.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 7.0
Polar Surface Area 173.51
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 30.0
Assay Description Organism Bioactivity Reference
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 3 60 kDa Escherichia coli 0.1 %
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 4 49 kDa Escherichia coli 100.0 %
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 1a 90 kDa Escherichia coli 0.1 %
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 1b 90 kDa Escherichia coli 0.5 %
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as penicillin-binding protein 2 66 kDa Escherichia coli 100.0 %
Evaluated for concentration required for 90 % inhibition of [14C]- penicillin G binding to PBP's of Escherichia coli UB 1005 as Penicillin-binding protein 5/6 40 kDa Escherichia coli 100.0 %
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP1 by competitive binding assay Staphylococcus aureus 0.25 ug.mL-1
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP1 by competitive binding assay Staphylococcus aureus 2.0 ug.mL-1
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP1 by competitive binding assay Staphylococcus aureus 0.5 ug.mL-1
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP1 by competitive binding assay Staphylococcus aureus 4.0 ug.mL-1
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP1 by competitive binding assay Staphylococcus aureus 1.0 ug.mL-1
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP1 by competitive binding assay Staphylococcus aureus 16.0 ug.mL-1
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP2 by competitive binding assay Staphylococcus aureus 0.25 ug.mL-1
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2 by competitive binding assay Staphylococcus aureus 0.5 ug.mL-1
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2 by competitive binding assay Staphylococcus aureus 0.25 ug.mL-1
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2 by competitive binding assay Staphylococcus aureus 1.0 ug.mL-1
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2 by competitive binding assay Staphylococcus aureus 1.0 ug.mL-1
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2 by competitive binding assay Staphylococcus aureus 2.0 ug.mL-1
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2a by competitive binding assay Staphylococcus aureus 128.0 ug.mL-1
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2a by competitive binding assay Staphylococcus aureus 1.0 ug.mL-1
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2a by competitive binding assay Staphylococcus aureus 128.0 ug.mL-1
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2a by competitive binding assay Staphylococcus aureus 2.0 ug.mL-1
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2a by competitive binding assay Staphylococcus aureus 0.25 ug.mL-1
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP3 by competitive binding assay Staphylococcus aureus 1.0 ug.mL-1
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP3 by competitive binding assay Staphylococcus aureus 0.25 ug.mL-1
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP3 by competitive binding assay Staphylococcus aureus 0.25 ug.mL-1
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP3 by competitive binding assay Staphylococcus aureus 2.0 ug.mL-1
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP3 by competitive binding assay Staphylococcus aureus 1.0 ug.mL-1
Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP3 by competitive binding assay Staphylococcus aureus 1.0 ug.mL-1
Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP4 by competitive binding assay Staphylococcus aureus 8.0 ug.mL-1
Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP4 by competitive binding assay Staphylococcus aureus 128.0 ug.mL-1
Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP4 by competitive binding assay Staphylococcus aureus 128.0 ug.mL-1
Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP4 by competitive binding assay Staphylococcus aureus 128.0 ug.mL-1
Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP4 by competitive binding assay Staphylococcus aureus 128.0 ug.mL-1
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1A by competitive binding assay Streptococcus pneumoniae 0.1 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1A by competitive binding assay Streptococcus pneumoniae 0.125 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1A by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1A by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1B by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1B by competitive binding assay Streptococcus pneumoniae 8.0 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1B by competitive binding assay Streptococcus pneumoniae 4.0 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1B by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2X by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2X by competitive binding assay Streptococcus pneumoniae 1.0 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2X by competitive binding assay Streptococcus pneumoniae 4.0 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2X by competitive binding assay Streptococcus pneumoniae 0.1 ug.mL-1
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2A by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2A by competitive binding assay Streptococcus pneumoniae 0.5 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2A by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2A by competitive binding assay Streptococcus pneumoniae 0.25 ug.mL-1
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2B by competitive binding assay Streptococcus pneumoniae 32.0 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2B by competitive binding assay Streptococcus pneumoniae 16.0 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2B by competitive binding assay Streptococcus pneumoniae 16.0 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2B by competitive binding assay Streptococcus pneumoniae 4.0 ug.mL-1
Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP3 by competitive binding assay Streptococcus pneumoniae 0.1 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP3 by competitive binding assay Streptococcus pneumoniae 0.1 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP3 by competitive binding assay Streptococcus pneumoniae 0.1 ug.mL-1
Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP3 by competitive binding assay Streptococcus pneumoniae 0.1 ug.mL-1
Bactericidal activity against Escherichia coli ATCC 25922 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs Escherichia coli 10.0 %
Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as eradication of pre-formed biofilm at 50 times MIC after 24 hrs Pseudomonas aeruginosa 10.0 %
Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-30 using cephalothin as reporter substrate Escherichia coli 300.0 nM
Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-2 using cephalothin as reporter substrate Escherichia coli 5.0 nM
Activity of Acinetobacter baumannii ADC-33 beta-lactamase Acinetobacter baumannii 500.0 nM
TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells None 290.0 nM
Antimicrobial activity against Candida albicans ATCC 90028 assessed as inhibition of microbial growth by CLSI based method Candida albicans 200.0 nM
Antimicrobial activity against Aspergillus fumigatus ATCC 90906 assessed as inhibition of microbial growth by CLSI based method Aspergillus fumigatus 200.0 nM
Antimicrobial activity against Cryptococcus neoformans ATCC 90113 assessed as inhibition of microbial growth by CLSI based method Cryptococcus neoformans 200.0 nM
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of microbial growth by CLSI based method Staphylococcus aureus 30.0 nM
Antimicrobial activity against Escherichia coli ATCC 35218 assessed as inhibition of microbial growth by CLSI based method Escherichia coli 100.0 nM
Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of microbial growth by CLSI based method Pseudomonas aeruginosa 30.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 4.74 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.11 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.11 %

Related Entries

Cross References

Resources Reference
ChEBI 204928
ChEMBL CHEMBL1730
DrugBank DB00493
DrugCentral 546
FDA SRS N2GI8B1GK7
Human Metabolome Database HMDB0014636
Guide to Pharmacology 10893
KEGG C06885
PDB CE3
PubChem 5742673
SureChEMBL SCHEMBL3731931
ZINC ZINC000004468780